Nuclear Medicine Studies in Metabolic Bone Disease

ABSTRACT

The principal application of nuclear medicine in metabolic bone disease is the isotope bone scan. Often, it is not a diagnostic tool but can be useful in clarifying the nature of a clinical problem. The best-established role for the bone scan in metabolic bone disease is in Paget's disease, in which it is diagnostic, provides definition of the extent of disease, and probably reflects disease activity. The isotope bone scan is also important in osteoporosis, for which it is not diagnostic but may often provide useful information to confirm that fracture has occurred, determine the age of the fracture, identify unsuspected fractures, and identify other causes for pain, for example, facet joint disease. The bone scan is less useful in other metabolic bone diseases, for example, renal osteodystrophy and osteomalacia, but will often have a characteristic appearance, with several metabolic features. The degree of positivity of the scan generally relates to the severity of the hyperparathyroidism. In patients with metabolic bone disease, other specific clinical problems may arise, such as osteomyelitis or avascular necrosis, and the bone scan may be diagnostic in these conditions. Nuclear medicine techniques are also of value in hyperparathyroidism and to localize the site of the adenoma where surgical treatment is being considered; the use of technetium Tc 99m sestamibi is now routine. More recently, positron emission tomography (PET) scanning has been found to be helpful in the more difficult cases.

KEYWORD

Metabolic bone - bone scan - PET - sestamibi

REFERENCES

• 1 Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget's disease.  Eur J Nucl Med . 1980;  5 417-421
• 2 Ryan P J, Gibson T, Fogelman I. Bone scintigraphy following pamidronate therapy for Paget's disease.  J Nucl Med . 1992;  33 1589-1593
• 3 Shirazi P H, Ryan W G, Fordham E W. Bone scanning in evaluation of Paget's disease of the bone.  CRC Crit Rev Clin Radiol Nucl Med . 1974;  5 523-558
• 4 Fogelman I, Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease.  Clin Radiol . 1980;  31 321-326
• 5 Deutsch A I, Mink J H, Waxman A D. Occult fractures of the proximal femur: MR imaging.  Radiology . 1989;  170 113-116
• 6 Ryan P J, Evans P A, Gibson T. Osteoporosis and chronic back pain: a study with single photon emission computed bone scintigraphy.  J Bone Miner Res . 1992;  33 1589-1593
• 7 Fogelman I, Citrin D L, Turner J G. Semi-quantitative interpretation of the bone scan in metabolic bone disease.  Eur J Nucl Med . 1979;  4 287-289
• 8 Cavalli P L, Camuzzini G F, Ghezzi P. Total body gammography in uraemic patients.  Minerva Nefrol . 1976;  23 142-148
• 9 Olgaard K, Heerfordj J, Iasden S. Scinitigraphic skeletal changes in uraemic patients on regular haemodialysis.  Nephron . 1976;  17 325-333
• 10 De Graaf P, Schicht I M, Pauwels E KJ, te Velde J, De Graeff J. Bone scintigraphy in renal osteodystrophy.  J Nucl Med . 1978;  19 1289-1296
• 11 Fogelman I, MacKillop J H, Greig W R. Pseudofractures of the ribs detected by bone scanning.  J Nucl Med . 1977;  18 1236-1237
• 12 Kim K Y, Lee S H, Moon D H. The diagnostic value of triple head single photon emission computed tomography (3H-SPECT) in a vascular necrosis of the femoral head.  Int Orthop . 1993;  17 132-138
• 13 Doppman J L, Miller D L. Localisation of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery.  J Bone Mineral Res . 1991;  6 S153-S158
• 14 Doppman J L, Skarulis M C, Chang R. Hypocalcaemic stimulation and nonselective venous sampling for localizing parathyroid adenomas.  Radiology . 1998;  208 145-151
• 15 Johnston B, Carroll M J, Britton K E. The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging.  J Clin Endocrinol Metab . 1996;  81 346-352
• 16 Hellman P, Ahlstrom H, Bergstrom M. Positron emission tomography with 11C-methionine in hyperparathyroidism.  Surgery . 1994;  116 974-981
• 17 Sundin A, Johansson C, Hellman P. PET and parathyroid L-[carbon-11] methionine accumulation in hyperparathyroidism.  J Nucl Med . 1996;  37 1766-1770
• 18 Cook G JR, Wong J CH, Smellie W JB. [11C] Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism.  Eur J Endocrinol . 1998;  139 195-197